SI2542079T1 - Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata - Google Patents

Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata

Info

Publication number
SI2542079T1
SI2542079T1 SI201130210T SI201130210T SI2542079T1 SI 2542079 T1 SI2542079 T1 SI 2542079T1 SI 201130210 T SI201130210 T SI 201130210T SI 201130210 T SI201130210 T SI 201130210T SI 2542079 T1 SI2542079 T1 SI 2542079T1
Authority
SI
Slovenia
Prior art keywords
laquinimod
methotrexate
treatment
combination
rheumatoid arthritis
Prior art date
Application number
SI201130210T
Other languages
English (en)
Inventor
Eran Blaugrund
Nora Tarcic
Joel Kaye
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2542079(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of SI2542079T1 publication Critical patent/SI2542079T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201130210T 2010-03-03 2011-03-02 Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata SI2542079T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33937510P 2010-03-03 2010-03-03
EP11751300.2A EP2542079B1 (en) 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PCT/US2011/026885 WO2011109531A1 (en) 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Publications (1)

Publication Number Publication Date
SI2542079T1 true SI2542079T1 (sl) 2014-08-29

Family

ID=44531858

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130210T SI2542079T1 (sl) 2010-03-03 2011-03-02 Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata

Country Status (21)

Country Link
US (1) US8501766B2 (sl)
EP (1) EP2542079B1 (sl)
JP (1) JP5819328B2 (sl)
KR (1) KR20130014523A (sl)
CN (2) CN105796556A (sl)
AU (1) AU2011223697B2 (sl)
BR (1) BR112012022187A2 (sl)
CA (1) CA2791709A1 (sl)
CL (1) CL2012002424A1 (sl)
CO (1) CO6630085A2 (sl)
DK (1) DK2542079T3 (sl)
EA (1) EA201290860A1 (sl)
ES (1) ES2476368T3 (sl)
MX (1) MX2012010066A (sl)
NZ (1) NZ602478A (sl)
PE (1) PE20130690A1 (sl)
PT (1) PT2542079E (sl)
SG (1) SG183513A1 (sl)
SI (1) SI2542079T1 (sl)
WO (1) WO2011109531A1 (sl)
ZA (1) ZA201207128B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53666B1 (en) * 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
DK2035001T3 (da) 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
ES2548999T3 (es) * 2009-06-19 2015-10-22 Teva Pharmaceutical Industries Ltd. Tratamiento de la esclerosis múltiple con laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
MX337614B (es) * 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
CN102984939A (zh) 2010-07-09 2013-03-20 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
PE20050232A1 (es) * 2003-06-25 2005-04-01 Elan Pharm Inc Metodo y composiciones para tratar la artritis reumatoide
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
JP2007531735A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤および該節約剤を使用する方法
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
RS53666B1 (en) * 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
CN101346353B (zh) * 2005-10-26 2012-01-11 默克雪兰诺有限公司 磺酰胺衍生物及其在调节金属蛋白酶中的用途
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
CA2641513C (en) * 2006-02-28 2021-09-21 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
KR20080104343A (ko) * 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
DK2035001T3 (da) * 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
EP2056818B1 (en) * 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
JP2010513518A (ja) 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
CN101848712B (zh) * 2007-07-11 2013-07-24 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病
SI2234485T1 (sl) * 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
ES2548999T3 (es) * 2009-06-19 2015-10-22 Teva Pharmaceutical Industries Ltd. Tratamiento de la esclerosis múltiple con laquinimod
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
AU2010282948C1 (en) * 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
ES2601819T3 (es) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
MX337614B (es) * 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
MX2013000332A (es) * 2010-07-09 2013-02-26 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
CN102984939A (zh) * 2010-07-09 2013-03-20 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
KR20130124518A (ko) * 2010-12-07 2013-11-14 테바 파마슈티컬 인더스트리즈 리미티드 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도
EA201490377A1 (ru) 2011-07-28 2014-11-28 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EP2736336A4 (en) 2011-07-28 2015-03-04 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA

Also Published As

Publication number Publication date
CL2012002424A1 (es) 2012-12-21
ZA201207128B (en) 2014-04-30
EA201290860A1 (ru) 2013-04-30
CA2791709A1 (en) 2011-09-09
EP2542079B1 (en) 2014-05-21
PT2542079E (pt) 2014-07-18
DK2542079T3 (da) 2014-08-25
AU2011223697A1 (en) 2012-10-11
EP2542079A1 (en) 2013-01-09
AU2011223697B2 (en) 2016-07-14
US8501766B2 (en) 2013-08-06
SG183513A1 (en) 2012-09-27
JP5819328B2 (ja) 2015-11-24
US20110218203A1 (en) 2011-09-08
PE20130690A1 (es) 2013-07-07
NZ602478A (en) 2014-09-26
EP2542079A4 (en) 2013-07-24
BR112012022187A2 (pt) 2015-09-22
MX2012010066A (es) 2012-10-03
JP2013521304A (ja) 2013-06-10
KR20130014523A (ko) 2013-02-07
CN102781240A (zh) 2012-11-14
CO6630085A2 (es) 2013-03-01
WO2011109531A1 (en) 2011-09-09
CN105796556A (zh) 2016-07-27
ES2476368T3 (es) 2014-07-14

Similar Documents

Publication Publication Date Title
ZA201207128B (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
GB201014633D0 (en) Rheumatoid arthritis treatment
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1177876A1 (zh) 用拉喹莫德來治療狼瘡性關節炎
EP2713727A4 (en) COMBINATION OF MEK INHIBITORS AND AURORA A KINASE ALECTIVE INHIBITORS
SG10201505624VA (en) Methods of treating rheumatoid arthritis using il-17 antagonists
EP2571570A4 (en) APPARATUS AND ELECTROSTIMULATION FOR ARTHRITIS
ZA201208173B (en) Peptices and their use
IL265950A (en) Detection and treatment of leprosy
EP2558137A4 (en) METHODS AND COMBINATION
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
HK1249427A1 (zh) 關節炎治療
HK1201538A1 (en) Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis 14-3-3
EP2540048A4 (en) ZERO DELAY GIGABIT BYPASS AND ASSOCIATED METHODS
HK1180726A1 (en) Kras primers and probes kras
IL286709A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
GB201001300D0 (en) Body support and teaching aid
GB201018488D0 (en) Teaching and learning aid
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201103281D0 (en) Transportable feeder and pen unit
ZA201104629B (en) Closure and closure arrangement
GB201020752D0 (en) Flue joint and support
GB201013139D0 (en) An improved bed and bath
GB201008694D0 (en) An improved bed and bath